ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
19 announcements
Vilin Bio Med Limited announced an NCLT-convened meeting on October 15, 2026, to vote on a Scheme of Arrangement with Chemgenix Laboratories Private Limited.
Vilin Bio Med Limited scheduled a board meeting for September 18, 2026, to consider an amalgamation proposal. Trading window remains closed until September 20, 2026.
Vilin Bio Med disclosed NCLT Hyderabad allowed its amalgamation with Chemgenix Laboratories Pvt Ltd. The order directs convening shareholder and creditor meetings for both companies.
Vilin Bio Med Limited conducted its 20th Annual General Meeting on September 2, 2026, to discuss financial statements, director appointments, and related party transactions.
Vilin Bio Med received a 'No Objection' observation letter from the NSE regarding its merger with Chemgenix Laboratories. The scheme remains subject to further statutory and creditor approvals.
Vilin Bio Med Limited has issued a notice for its 20th Annual General Meeting to be held on September 2, 2026, via video conferencing.
Vilin Bio Med has signed an MOU with Ideal Pharma BV to distribute generic and branded medicines across Europe. The partnership utilizes Ideal Pharma's distribution infrastructure.
Vilin Bio Med is incorporating two wholly-owned subsidiaries, Vilo Speciality Pharma and Axia Pharma. These entities will focus on pharmaceutical marketing, distribution, and manufacturing.
Vilin Bio Med appointed Neha Lahoti as Company Secretary and Compliance Officer. Anjali Choudhary resigned from the same position effective June 27, 2026.
Vilin Bio Med appointed Ms. Shivani Pallapu as CFO and accepted the resignation of Mr. Avula Hari Prasad. The leadership change aims to strengthen financial management.
CFO Mr. Avula Hariprasad resigned effective June 11, 2026 due to personal reasons. The company must now appoint a new CFO to ensure financial leadership continuity.
Vilin Bio Med Limited submitted a non-applicability certificate for the Annual Secretarial Compliance Report. The company is exempt from Regulation 24A as an SME-listed entity.
Vilin Bio Med Ltd reported revenue from operations of ₹32.6 Cr (+216.5% YoY) and net profit of ₹1.8 Cr (+1700.0% YoY) for H2 FY26.
Vilin Bio Med reported its FY2026 audited financial results following board approval. The company maintained steady operations with no reported deviations in fund utilization.
Vilin Bio Med Limited filed its annual SDD Compliance Certificate for the financial year ended March 31, 2026. The certification confirms full regulatory database compliance.
Vilin Bio Med Limited scheduled a board meeting for May 30, 2026, to approve audited annual financial results. Trading window remains closed for designated persons.
Vilin Bio Med Limited announced the reclassification of Mr. Devireddy Srinivas Reddy from promoter to public category. The change follows the completion of an Open Offer.
Vilin Bio Med Limited has received trading approval from the National Stock Exchange for 13,00,000 equity shares of Rs.10/- each. These shares were issued on a preferential allotment basis. The approval facilitates the secondary market trading of these newly allotted securities.
Vilin Bio Med Limited promoters have submitted an annual declaration confirming that no shares were encumbered, directly or indirectly, during the financial year ended March 31, 2026. This disclosure is a standard regulatory requirement under SEBI SAST Regulations to maintain transparency regarding promoter shareholdings.